Levi & Korsinsky notifies investors that it has commenced an investigation into Axogen, Inc. (NASDAQ: AXGN) concerning potential violations of the federal securities laws.
Axogen issued a press release on August 25, 2025, "announcing that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by three months to December 5, 2025." Following this news, Axogen's stock price fell over 9% on August 25, 2025.
If you suffered a loss on your Axogen, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





